- Records
- 19
- Recruiting
- 11
- Recruiting sites
- 613
- Countries
- 18
ClinicalTrials.gov registry snapshot / 2026-07-24Peptide trials,
Peptide trials,
without the maze.
Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.
268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program
Study status is not drug rank.
Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.
- Records
- 52
- Recruiting
- 10
- Recruiting sites
- 170
- Countries
- 7
- Records
- 37
- Recruiting
- 10
- Recruiting sites
- 73
- Countries
- 3
- Records
- 24
- Recruiting
- 10
- Recruiting sites
- 935
- Countries
- 28
- Records
- 27
- Recruiting
- 6
- Recruiting sites
- 1,581
- Countries
- 36
- Records
- 30
- Recruiting
- 5
- Recruiting sites
- 155
- Countries
- 6
- Records
- 8
- Recruiting
- 4
- Recruiting sites
- 339
- Countries
- 23
- Records
- 31
- Recruiting
- 3
- Recruiting sites
- 774
- Countries
- 34
- Records
- 15
- Recruiting
- 3
- Recruiting sites
- 3
- Countries
- 1
- Records
- 34
- Recruiting
- 2
- Recruiting sites
- 450
- Countries
- 27
- Records
- 9
- Recruiting
- 2
- Recruiting sites
- 4
- Countries
- 3
- Records
- 9
- Recruiting
- 1
- Recruiting sites
- 8
- Countries
- 1
- Records
- 5
- Recruiting
- 0
- Recruiting sites
- 0
- Countries
- 0
Official registry finder
Filter the exact records.
Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.
34matching registry records
Snapshot timestampJuly 24, 2026 at 9:00 AM UTC
| Program and record | Status | Phase and enrollment | Locations | Primary completion | Registry update | Source |
|---|---|---|---|---|---|---|
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 34,500 estimated | 449 recruiting563 listed / 34 countries | Aug 2030estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07165028 ↗ |
| Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are OverweightNCT07467447 / GZBF / Hudson Biotech | RecruitingVerified 2026-03 | Phase 2300 estimated | 1 recruiting1 listed / 1 countries | Mar 14, 2027estimated | Mar 12, 2026ClinicalTrials.gov | Open NCT07467447 ↗ |
| A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045 / TRIUMPH-3 / Eli Lilly and Company | Active, not recruitingVerified 2026-05 | Phase 31,946 actual | 0 recruiting169 listed / 10 countries | Apr 16, 2026actual | May 22, 2026ClinicalTrials.gov | Open NCT05882045 ↗ |
| A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079 / TRIUMPH-2 / Eli Lilly and Company | Active, not recruitingVerified 2026-04 | Phase 31,000 estimated | 0 recruiting98 listed / 8 countries | May 2026estimated | Apr 13, 2026ClinicalTrials.gov | Open NCT05929079 ↗ |
| Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722 / Eli Lilly and Company | Active, not recruitingVerified 2026-04 | Phase 31,250 estimated | 0 recruiting77 listed / 5 countries | Aug 2026estimated | Apr 13, 2026ClinicalTrials.gov | Open NCT06260722 ↗ |
| Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 3320 estimated | 0 recruiting76 listed / 7 countries | Oct 2026estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06297603 ↗ |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 310,000 estimated | 0 recruiting743 listed / 27 countries | Feb 2029estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06383390 ↗ |
| A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383 / TRIUMPH-5 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 3800 estimated | 0 recruiting65 listed / 5 countries | Nov 2026estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06662383 ↗ |
| A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityNCT06859268 / TRIUMPH-6 / Eli Lilly and Company | Active, not recruitingVerified 2026-02 | Phase 3643 estimated | 0 recruiting53 listed / 3 countries | Apr 2028estimated | Mar 3, 2026ClinicalTrials.gov | Open NCT06859268 ↗ |
| A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusNCT06982859 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 195 estimated | 0 recruiting1 listed / 1 countries | Dec 2026estimated | Jul 16, 2026ClinicalTrials.gov | Open NCT06982859 ↗ |
| A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093 / TRIUMPH-7 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 3586 estimated | 0 recruiting40 listed / 4 countries | Sep 2027estimated | Jul 23, 2026ClinicalTrials.gov | Open NCT07035093 ↗ |
| A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719 / TRIUMPH-8 / Eli Lilly and Company | Active, not recruitingVerified 2026-04 | Phase 3250 estimated | 0 recruiting31 listed / 2 countries | Jul 2027estimated | Apr 17, 2026ClinicalTrials.gov | Open NCT07232719 ↗ |
| A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightNCT07357415 / TRIUMPH-9 / Eli Lilly and Company | Active, not recruitingVerified 2026-06 | Phase 3600 estimated | 0 recruiting35 listed / 3 countries | Oct 2028estimated | Jun 9, 2026ClinicalTrials.gov | Open NCT07357415 ↗ |
| Provide Pre-approval Expanded Access of LY3437943NCT07629401 / Eli Lilly and Company | AvailableVerified 2026-06 | Not applicableEnrollment not stated | 0 recruiting0 listed / 0 countries | Not statedType not stated | Jun 5, 2026ClinicalTrials.gov | Open NCT07629401 ↗ |
| A Safety Study of LY3437943 Given as a Single Injection in Healthy ParticipantsNCT03841630 / Eli Lilly and Company | CompletedVerified 2019-08 | Phase 145 actual | 0 recruiting1 listed / 1 countries | Jul 25, 2019actual | Aug 6, 2019ClinicalTrials.gov | Open NCT03841630 ↗ |
| A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)NCT04143802 / Eli Lilly and Company | CompletedVerified 2021-01-15 | Phase 172 actual | 0 recruiting4 listed / 1 countries | Dec 28, 2020actual | Jan 20, 2021ClinicalTrials.gov | Open NCT04143802 ↗ |
| A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)NCT04823208 / Eli Lilly and Company | CompletedVerified 2022-08 | Phase 164 actual | 0 recruiting4 listed / 1 countries | Jun 23, 2022actual | Aug 22, 2022ClinicalTrials.gov | Open NCT04823208 ↗ |
| A Study of LY3437943 in Participants With Type 2 DiabetesNCT04867785 / Eli Lilly and Company | CompletedVerified 2023-06Registry results posted | Phase 2281 actual | 0 recruiting43 listed / 2 countries | Jul 8, 2022actual | Jul 3, 2023ClinicalTrials.gov | Open NCT04867785 ↗ |
| A Study of LY3437943 in Participants Who Have Obesity or Are OverweightNCT04881760 / Eli Lilly and Company | CompletedVerified 2023-08Registry results posted | Phase 2338 actual | 0 recruiting28 listed / 2 countries | May 16, 2022actual | Sep 13, 2023ClinicalTrials.gov | Open NCT04881760 ↗ |
| A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese ParticipantsNCT05445232 / Eli Lilly and Company | CompletedVerified 2023-04-01 | Phase 132 actual | 0 recruiting2 listed / 1 countries | Feb 24, 2023actual | Apr 18, 2023ClinicalTrials.gov | Open NCT05445232 ↗ |
| A Study of LY3437943 in Chinese Participants With Obesity Or OverweightNCT05548231 / Eli Lilly and Company | CompletedVerified 2023-08 | Phase 132 actual | 0 recruiting2 listed / 1 countries | Jul 27, 2023actual | Aug 14, 2023ClinicalTrials.gov | Open NCT05548231 ↗ |
| A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal FunctionNCT05611957 / Eli Lilly and Company | CompletedVerified 2023-09-15 | Phase 129 actual | 0 recruiting4 listed / 1 countries | Sep 5, 2023actual | Oct 2, 2023ClinicalTrials.gov | Open NCT05611957 ↗ |
| A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male ParticipantsNCT05757531 / Eli Lilly and Company | CompletedVerified 2023-07 | Phase 17 actual | 0 recruiting1 listed / 1 countries | Jun 23, 2023actual | Jul 5, 2023ClinicalTrials.gov | Open NCT05757531 ↗ |
| A Study of LY3437943 in Participants With Impaired and Normal Liver FunctionNCT05916560 / Eli Lilly and Company | CompletedVerified 2025-04 | Phase 143 actual | 0 recruiting5 listed / 1 countries | Mar 2, 2025actual | Apr 18, 2025ClinicalTrials.gov | Open NCT05916560 ↗ |
| A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066 / TRIUMPH-1 / Eli Lilly and Company | CompletedVerified 2026-06 | Phase 32,335 actual | 0 recruiting134 listed / 12 countries | Apr 6, 2026actual | Jun 3, 2026ClinicalTrials.gov | Open NCT05929066 ↗ |
| A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367 / TRIUMPH-4 / Eli Lilly and Company | CompletedVerified 2026-01 | Phase 3445 actual | 0 recruiting49 listed / 6 countries | Nov 14, 2025actual | Jan 21, 2026ClinicalTrials.gov | Open NCT05931367 ↗ |
| A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151 / Eli Lilly and Company | CompletedVerified 2025-11 | Phase 2146 actual | 0 recruiting42 listed / 5 countries | Oct 1, 2025actual | Nov 25, 2025ClinicalTrials.gov | Open NCT05936151 ↗ |
| A Study of LY3437943 in Healthy Participants With a High Body Mass IndexNCT05959096 / Eli Lilly and Company | CompletedVerified 2024-09 | Phase 185 actual | 0 recruiting1 listed / 1 countries | Jul 25, 2024actual | Oct 1, 2024ClinicalTrials.gov | Open NCT05959096 ↗ |
| A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection DevicesNCT06003465 / Eli Lilly and Company | CompletedVerified 2024-03 | Phase 157 actual | 0 recruiting3 listed / 1 countries | Feb 8, 2024actual | Mar 29, 2024ClinicalTrials.gov | Open NCT06003465 ↗ |
| A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or ObeseNCT06039826 / Eli Lilly and Company | CompletedVerified 2024-07 | Phase 146 actual | 0 recruiting2 listed / 1 countries | Jul 11, 2024actual | Jul 26, 2024ClinicalTrials.gov | Open NCT06039826 ↗ |
| A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943NCT06313528 / Eli Lilly and Company | CompletedVerified 2025-09 | Phase 185 actual | 0 recruiting3 listed / 1 countries | Aug 26, 2025actual | Sep 23, 2025ClinicalTrials.gov | Open NCT06313528 ↗ |
| Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)NCT06354660 / Eli Lilly and Company | CompletedVerified 2026-03 | Phase 3537 actual | 0 recruiting48 listed / 4 countries | Jan 22, 2026actual | Mar 5, 2026ClinicalTrials.gov | Open NCT06354660 ↗ |
| To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy ParticipantsNCT06808802 / Eli Lilly and Company | CompletedVerified 2025-06 | Phase 130 actual | 0 recruiting1 listed / 1 countries | Apr 15, 2025actual | Jun 5, 2025ClinicalTrials.gov | Open NCT06808802 ↗ |
| A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaNCT06982846 / Eli Lilly and Company | CompletedVerified 2026-06 | Phase 180 actual | 0 recruiting1 listed / 1 countries | May 4, 2026actual | Jun 18, 2026ClinicalTrials.gov | Open NCT06982846 ↗ |
Recruiting location footprint
Country and US state routes.
Counts are site observations across registry records, not unique facilities. The same research center can appear in multiple studies. Open the exact NCT record before treating a location as current.
Clinical trial finder FAQ
Status, location, and enrollment are different fields.
These answers prevent the most common registry-search errors before a reader follows an official source.
Are any Retatrutide clinical trials recruiting?
Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.
How do I find a peptide clinical trial near me?
Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.
Does Recruiting mean I can join the trial?
No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.
Are the drugs in this clinical trial finder FDA approved?
A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.
Why do only some registry records show posted results?
11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.
How current is the peptide clinical trial data?
The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.
Evidence boundary
A registry finder, not an enrollment service.
A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.
Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.
Read the official API documentation ↗Understand evidence categories →